Subtype
Nasopharyngeal Carcinoma
CI-CAN-00008100NPCExplore in graph →
246 active trials1 approved drugs
- NCIt
- C3871
- OncoTree
- NPC
- UMLS CUI
- C2931822
- MeSH
- D000077274
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00008100NPCExplore in graph →
Clinical trials
702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 |
| clinicaltrials |
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | suspended | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06629597 | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | active not recruiting | Phase 3 | 400 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 710 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824856 | Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06029270 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | recruiting | Phase 2 | 156 | National Cancer Institute (NCI)NIH | 5 | Sep 16, 2026 | clinicaltrials |
| NCT07797881 | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07783321 | A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819656 | Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma | recruiting | — | 1,782 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06064097 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | active not recruiting | Phase 2 / Phase 3 | 924 | NRG OncologyOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT06763289 | Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection(PROFOUND-NPC) | active not recruiting | — | 700 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07625423 | Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors(EDS01 HN) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06787456 | "Xijiang Project" Screening Cohort for NPC | recruiting | — | 1,000,000 | Ming-Yuan ChenOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796789 | Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05126719 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 238 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06976190 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(Magic-C002) | recruiting | Phase 3 | 446 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07794488 | Platinum-Free Regimen in Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 145 | Zhejiang Cancer HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07137052 | Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma | recruiting | — | 732 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07201337 | Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. | active not recruiting | Phase 3 | 700 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789158 | Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 269 | Fudan UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04456322 | Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 381 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04910347 | Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 57 | Yonsei UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781358 | Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. | recruiting | Phase 2 | 25 | Hongmeng YuOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05245682 | Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | active not recruiting | Early Phase 1 | 10 | Emory UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07636499 | Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy | active not recruiting | Phase 1 | 50 | Guiquan ZhuOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06532279 | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | recruiting | Phase 2 | 98 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07764887 | Impacted Tooth Management and Osteoradionecrosis Risk in NPC | not yet recruiting | N/A | 536 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06712888 | Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma(Navigation) | active not recruiting | Phase 3 | 466 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07762976 | Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 2 | 148 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05979961 | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 464 | Sun Yat-sen UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07650266 | A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma | not yet recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07756190 | Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study(RADIANCE) | not yet recruiting | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03803774 | Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741110 | Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy | completed | — | 141 | Hellenic Cooperative Oncology GroupOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | active not recruiting | Phase 2 / Phase 3 | 430 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06854510 | Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. | active not recruiting | Phase 2 / Phase 3 | 196 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 570 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07528183 | Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06662058 | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation | recruiting | N/A | 118 | Emory UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07064902 | Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706985 | Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 566 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705243 | Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 86 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials